Evidence map›Paper›PMID 42284009›Full record

ArticleCurrent medical science2026

Burden and Long-Term Trends of Viral Hepatitis in China: A National and Provincial Analysis.

Jing-Yi Peng, Xin-Yu Xiang, Jie Zhang, Yuan Yuan, Yang Ding, Yu-Chen Xia, You-de Xiao, Xing-Xing He

Abstract read
PubMed Publisher
In one paragraph

Article in Current medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jing-Yi Peng *Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Xin-Yu Xiang *Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Jie ZhangDepartment of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Yuan YuanDepartment of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Yang DingDepartment of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Yu-Chen XiaState Key Laboratory of Virology and Biosafety, Hubei Provincial Research Center for Basic Biological Sciences and Hubei Province Key Laboratory of Allergy and Immunology, Institute of Medical Virology, TaiKang Center for Life and Medical Sciences, TaiKang Medical School, Wuhan University, Wuhan, 430071, China.
You-de XiaoDepartment of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. 784412250@qq.com.
Xing-Xing HeDepartment of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. hexingxing@whu.edu.cn.ORCID http://orcid.org/0000-0003-0001-8473

Funding

2025 Regional Innovation Project of Hubei Provincial Department of Science and Technology No. 2025EIA001
6 · The paper itself

Abstract

objectiveViral hepatitis remains a major global health threat, causing approximately 1.3 million deaths in 2022. Despite substantial advances in vaccination and clinical treatment, it continues to impose a heavy disease burden across China. Existing studies have largely focused on single hepatitis subtypes and national epidemiological trends, with limited evidence on provincial heterogeneity. To fill this research gap, this study aimed to conduct a refined, region-specific epidemiological assessment of viral hepatitis in China.

methodsData were extracted from the Global Burden of Disease Study 2021 (GBD 2021) and the China Public Health Science Data Center to systematically analyze the epidemiological characteristics and spatiotemporal trends of viral hepatitis in China over the past three decades.

resultsThe overall burden of viral hepatitis in China decreased substantially over the study period, with obvious regional heterogeneity. Acute hepatitis A, B and E, as well as chronic hepatitis B and C, all presented prominent downward trends. The fastest declines in incidence were observed in acute hepatitis B (estimated annual percentage change [EAPC] = -3.03) and chronic hepatitis B (EAPC = -4.74). Notably, males suffered a higher disease burden for nearly all outcomes, except for HCV-related hepatocellular carcinoma, which predominantly affected females. Furthermore, provincial-level analysis indicated marked regional disparities: Xizang maintained a high incidence rate, while Beijing exhibited low incidence accompanied by strikingly high hepatitis-related mortality, suggesting a notable decoupling between infection prevalence and mortality.

conclusionsChina has achieved remarkable reductions in the overall burden of viral hepatitis, attributable to comprehensive public health interventions such as universal vaccination, standardized screening and improved sanitation conditions. Nevertheless, residual burdens in vulnerable populations and striking regional inequalities warrant targeted prevention and control strategies to reduce disease disparities nationwide.

Indexed as

Hepatitis, Viral, HumanAdultChinaCost of IllnessFemaleGlobal Burden of DiseaseHumansIncidenceMaleMiddle AgedChinaChina Public Health Science Data CenterDisease burdenGlobal Burden of Disease (GBD)Viral hepatitis

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.